Additionally, SW2_152F has been proven to inhibit the growth of triple-negative breast cancer cells and the neuroendocrine differentiation of prostate cancer cells, which indicated that CBX2 inhibitor could be a pan-cancer therapeutic agent [47, 48]. This evidence concerns the gene CBX2 and prostate carcinoma.